Concepedia

A Phase I Trial of Pemetrexed Plus Gemcitabine Given Biweekly with B-Vitamin Support in Solid Tumor Malignancies or Advanced Epithelial Ovarian Cancer

Martee L. Hensley, Joseph Larkin, Matthew G. Fury, Scott R. Gerst, D. F. Tai, Paul Sabbatini, Jason Konner, Mauro Orlando, T. Goss, Carol Aghajanian

Clinical Cancer Research · 2008 · 13 citations · 13 references

DOIFull text

Open access

Abstract

MTDs for the solid tumor and ovarian cancer cohorts were reached at pemetrexed 500 and 600 mg/m(2), respectively, given biweekly with gemcitabine 1,500 mg/m(2).

References

13

Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al. · Journal of Clinical Oncology · 2003 · 3K citations

Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma

Margaret A. Tempero, William Plunkett, Veronique Ruiz van Haperen et al. · Journal of Clinical Oncology · 2003 · 519 citations

Randomized Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer

David G. Mutch, Mauro Orlando, T. Goss et al. · Journal of Clinical Oncology · 2007 · 432 citations · Full text

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

Helmut Oettle, Donald Richards, Rajesh Ramanathan et al. · Annals of Oncology · 2005 · 304 citations · Full text

, , +8

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Clet Niyikiza, Sharyn D. Baker, David E. Seitz et al. · PubMed · 2002 · 247 citations

, , +11